Biotransformation of drugs during aging.
Although the biological half-lives of many drugs appear to be longer in the elderly than in the young, the reasons for these longer half-lives are seldom clear, because the pharmacokinetic data obtained in humans are seldom sufficient to make a proper pharmacokinetic analysis. In the present paper are outlined the kinds of data required, the reasons they are required, and the possible consequences resulting from misinterpretation of inadequate data.